Bonnie Hersh is a Neurology physician affiliated with Biogen. OpenAlex indexes 17 publications with 781 citations (h-index 8).
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
133 Brookline Ave
Boston, MA 022153904
Telephone
617-421-1020Provider last certified this registry record 6 Jan 2021.
Medicare prescribing footprint (2021)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Nervous system
96.2%Aromatic Amino Acid Decarboxylation Inhibitor45.9%Carbidopa-Levodopa49%Rytary29%Carbidopa-Levodopa Er17%Carbidopa4%Part D<11 patientsNonergot Dopamine Agonist12%Ropinirole Er88%Neupro12%Part D<11 patients+ 8 more classes in this area
Hormonal (systemic)
2.4%Mineralocorticoids2.4%Fludrocortisone Acetate100%Part D<11 patientsCardiovascular
1.4%Beta blocker1.4%Propranolol Hcl100%Part D<11 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
NIH funding
1 NIH research award on record, funded 2000–2001 per NIH RePORTER. The latest:
- EFFECT OF AN ORAL DOSE OF TYRAMINE IN PATIENTS WITH EARLY PARKINSON'S DISEASE
Boston University Medical Campus
FY2001M01RR000533
Awards in the NIH RePORTER records where a principal investigator name matches this physician at an organization in their practice state. Latest award years shown; each row links to the project record on RePORTER.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- <scp>LRRK2</scp> as a Potential Disease‐Modifying Target in Sporadic Parkinson's Disease
Movement Disorders
2025 - Rationale for LRRK2 inhibition in sporadic Parkinson’s disease and the LUMA trial
Parkinsonism & Related Disorders
2025 - The BEACON Study: LRRK2 inhibition by BIIB122/DNL151 in participants with Pathogenic LRRK2 Variants and Parkinson’s disease
Parkinsonism & Related Disorders
2025 - Head injury at early ages is associated with risk of Parkinson's disease
Parkinsonism & Related Disorders
2015
Similar KOLs
Other experts from the same institution or the same specialty.
Bruce Miller, MD
University of California, San Francisco (UCSF)
Bradley Boeve, MD
Mayo Clinic
Richard Lipton, MD
Albert Einstein College of Medicine
Steven Dekosky, MD
University of Florida Health
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments, shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”